The activity and expression of transgene ␤-galactosidase (lacZ) by replication-deficient adenoviral vectors (Ad-lacZ) containing prostate-specific promoters were compared using an in vivo canine model. The prostate tissue-specific promoters were prostate-specific antigen, probasin, and mouse mammary tumor virus long-terminal repeat, which were fused separately to an Escherichia coli lacZ gene. Dogs underwent laparotomy, and adenoviral vectors were delivered by direct intraprostatic injection. At 72 hours postinjection, the prostate and various other organs were harvested to evaluate the degree of prostate expression and dissemination of adenoviral vectors. Expression of lacZ in tissues was determined by 5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining, ␤-galactosidase assay, and E. coli lacZ reverse transcriptase-polymerase chain reaction (PCR). The presence of adenoviral DNA sequences in canine tissues was determined by PCR using primers specific for the type 5 adenoviral genome. All three of the prostate-specific adenoviruses tested effectively expressed the lacZ gene in the canine prostate, but expression levels were lower than that of the control viral vector AdRSVlacZ following intraprostatic injection. By PCR, adenoviral vector DNA was detected in other organs and tissues, including the bladder and vas deferens. However, reverse transcriptase-PCR analysis revealed that prostate-specific Ad-lacZ vectors only transcribed lacZ mRNA in the prostate and not in nonprostatic tissues. Thus, these novel prostate-specific adenoviral vectors each have equal in vivo expression exclusively in the prostate and may potentially be used for prostate cancer gene therapy.
P rostate cancer has become the most frequent cancer and a second leading cause of cancer deaths in men today. The majority of newly diagnosed patients will have advanced prostate cancer, for which current treatments cannot cure and the prognosis is dismal. A gene therapy approach may be a novel way to combat prostate cancer. Most viral-based vectors for gene therapy contain endogenous viral promoters that are tissue-nonspecific. Consequently, unintended expression of toxic therapeutic genes may theoretically occur in other normal tissues. Viral vectors that contain prostate-specific promoter elements may theoretically allow exclusive expression of a therapeutic gene in prostate tissues for regional and systemic gene therapy. This current study was designed to test whether a series of prostate-specific adenoviruses can specifically express a reporter transgene with reasonable activity in prostate tissues.
There are at least three putative prostate-specific promoters: prostate-specific antigen (PSA) promoter, probasin (PB) promoter, and mouse mammary tumor virus (MMTV) long-terminal repeat (LTR). PSA is a protease that is, for all practical purposes, exclusively expressed in the prostate. 1 PSA is overproduced by prostate cancer, and elevated serum PSA levels correlate with the volume of prostate cancer burden. [1] [2] [3] Circulating PSA-positive cells are also strongly associated with metastatic prostate cancer. 4 A 620-base pair (bp) PSA promoter isolated from a prostate cancer patient recently demonstrated prostate-specific expression of the reporter gene using an expression vector. 5 PB, a rat prostate protein, is also expressed selectively in the prostate. 6 In transgenic mice, the rat PB gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate. 7 Transgenic mice bearing the PB promoter fused to the simian virus 40 (SV40) large-tumor antigen gene all consistently develop prostate adenocarcinoma. 8 Similarly, MMTV LTR has specificity for both breast and prostate tissues as determined by studies in both cultured cells and transgenic mice. 9 -11 Retroviruses carrying MMTV LTR-antisense c-myc effectively inhibit the growth of prostate cancer DU145 cells in vivo. 12 MMTV LTR transforming growth factor-␤ transgenic mice have mammary 13, 14 and prostate 15 tissue hypoplasia. Whether these promoters in adenoviral vectors are prostate-specific in vivo remains unknown. A canine model was used to evaluate whether replication-deficient recombinant adenoviruses containing a lacZ re-porter gene driven by PSA, PB, or MMTV LTR promoters have prostate-specific expression in vivo.
MATERIALS AND METHODS
Construction of adenoviruses containing prostatespecific promoter fused to lacZ PB/SV40t is an expression vector containing a 456-bp 5Ј upstream region of rat PB gene. 7 To make AdPBlacZ, a 3.2-kilobase lacZ gene containing a nuclear localization signal at the 5Ј upstream was released from plasmid pPD1.27, a derivative of pPD16.43 16 by HindIII and DraI; after polishing the ends, the lacZ gene was ligated to PB/SV40t, which had been cut by EcoRV, so that lacZ was placed downstream of the 456-bp PB promoter. The resultant plasmid was cut by PstI and ApaI to release a PB-lacZ-poly(A) cassette; after polishing the ends, the cassette was subcloned into an E1a-deleted adenoviral type 5 shuttle vector, the endogenous Rous sarcoma virus (RSV) promoter of which had been removed, to generate the resultant recombinant adenoviral shuttle vector pPBlacZ.
A 650-bp 5Ј upstream region of human PSA gene and a 1.1-kilobase ClaI-truncated MMTV LTR (derived from pMAMneo, Clontech, Palo Alto, Calif) were used as the PSA promoter and MMTV LTR promoter. The adenoviral shuttle vectors pMMTVlacZ and pPSAlacZ were generated by replacing the PB promoter in pPBlacZ with the MMTV LTR promoter and the PSA promoter, respectively. All of the structures of the recombinant adenoviral shuttle vectors were confirmed by sequencing.
Recombinant adenoviruses AdPBlacZ, AdMMTVlacZ, and AdPSAlacZ were generated via in vivo recombination in 293 cells by the cotransfection of pJM17, an adenoviral genome plasmid, and their corresponding shuttle vectors pPBlacZ, pMMTVlacZ, and pPSAlacZ, respectively. Individual plaques were screened by direct plaque-screening polymerase chain reaction (PCR) 17 using primers specific for transgene (i.e., one primer specific for the promoter and the other primers specific for the lacZ gene). The primers specific for the three promoters (PB, PSA, and MMTV LTR) were 5Ј-GCTACTCTGCAC-CTTGTCAG-3Ј, 5Ј-GCTCCTGGGGGAGGCTCC-3Ј, and 5Ј-GCGGAACGGACTCACCATAG-3Ј. The primer specific for lacZ was 5Ј-TCTGGCCTTCCTGTAGCCAGC-3Ј. By a similar method, AdRSVlacZ, in which the lacZ gene was under the control of the RSV promoter, was generated.
In vivo delivery of adenoviral vectors
Using a canine model, each adenoviral vector of AdRSVlacZ, AdPBlacZ, AdPSAlacZ, and AdMMTVlacZ (4.8 ϫ 10 9 plaque-forming units each to one dog) was diluted in 1 mL of 0.9 M saline and delivered to one anesthetized dog (average age, 1.5 years; average weight, 22 kg) by intraprostatic (i.p.) injection. Briefly, laparotomy was performed, and 0.25 mL of viral solution was directly injected into each quadrant of the prostate (4 ϫ 0.25 mL ϭ 1 mL total). The dogs were sacrificed at 72 hours postinjection, and various organs (prostate, liver, lung, spleen, bladder, brain, heart, kidney, external and internal iliac arteries, gonads, and vas deferens) were obtained at necropsy.
5-bromo-
Tissue samples were processed and frozen in optimal cutting temperature compound (Tissue-Tek/Sakura, Torrance, Calif).
Cryosections were stained by lacZ substrate X-Gal solution (Life Technologies, Gaithersburg, Md) as described previously. 18 
␤-galactosidase (␤-gal) assay
Prostate tissue was homogenized in 100 L per 50-mm 3 sample of 1ϫ lysis buffer (␤-gal assay kit, Invitrogen, Carlsbad, Calif). After microcentrifugation at 14,000 revolutions per minute for 5 minutes at 4°C, the supernatant was collected. The protein concentration was determined by Coomassie Plus Protein Assay reagent (Pierce, Rockford, Ill). The colorimetric ␤-gal assay was performed using a ␤-gal assay kit (Invitrogen) according to the manufacturer's protocol.
PCR
Genomic DNA was isolated from organs and tissues using a QIAamp tissue kit (Qiagen, Clarita, Calif) according to the manufacturer's protocol. The primers were specific for adenoviral type 5 genome and resulted in an 860-bp PCR amplification fragment within the homologous recombination region. 19 Primer 1 was 5Ј-TCGTTTCTCAGCAGCTGTTG-3Ј; primer 2 was 5Ј-CATCTGAACTCAAAGCGTGG-3Ј. PCR was performed in a 50-L volume containing 250 ng DNA, 2 mM MgCl 2 , 50 mM KCl, 0.2 mM deoxynucleoside triphosphate, 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.4), 2 M each of the primers, and 2.5 U of Taq DNA polymerase (Life Technologies). The reaction was performed at 94°C for 5 minutes and subsequently for 30 cycles at 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute, followed by 10 minutes at 72°C.
Reverse transcriptase (RT)-PCR
Total RNA was isolated from organs and tissues using an RNeasy Total RNA Kit (Qiagen) according to the manufacturer's protocol. After treating total RNA with ribonucleasefree deoxyribonuclease I (Life Technologies), an RT reaction was performed using Superscript II RT (Life Technologies) according to the manufacturer's protocol. An aliquot of the RT mixture was subsequently used for the PCR reaction. The primers were specific for the Escherichia coli lacZ gene and resulted in a 1036-bp PCR amplification fragment. 20 Primer 1 was 5Ј-GCCGACCGCACGCCGCATCCAGC-3Ј; primer 2 was 5Ј-CGCCGCGCCACTGGTGTGGGCC-3Ј. PCR was performed in a 50-L total volume containing 5-10 L of the above RT mixture in a final concentration of 4 mM MgCl 2 , 50 mM KCl, 0.2 mM deoxynucleoside triphosphate, 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.4), 2 M each of the primers, and 2.5 U of Taq DNA polymerase (Life Technologies). The reaction was performed at 94°C for 4 minutes and subsequently for 30 cycles at 94°C for 1 minute, 60°C for 2 minutes, and 72°C for 2 minutes, followed by 10 minutes at 72°C. To ensure the quality of the total RNA samples, the same RT mixtures mentioned previously were used for PCR of the housekeeping gene ␤-actin. The primers specific for the ␤-actin gene were 5Ј-TCCTGTGGCATCCAC-GAAACT-3Ј and 5Ј-GAAGCATTTGCGGTGGACGAT-3Ј, which resulted a 314-bp PCR product. The same conditions for the PCR of lacZ were used for the PCR of ␤-actin, except the reaction was performed at 94°C for 4 minutes and subsequently for 30 cycles at 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, followed by 10 minutes at 72°C.
Southern blot
A standard Southern blot transfer of PCR or RT-PCR cDNA products from agarose gel to nylon membranes (Hybond-N ϩ ,
Amersham Life Science, Buckinghamshire, UK) was performed as described previously. 21 The 860-bp and 1036-bp PCR products (see above) from positive control plasmids were purified and used as probes for the PCR and RT-PCR Southern blots, respectively. The probe was labeled by [␣- 32 P]deoxycytidine triphosphate using the random primer method (Prime-It II kit, Stratagene, La Jolla, Calif). The membrane was hybridized with the probe in Rapid-hyb buffer (Amersham Life Science) according to the manufacturer's protocol. The membrane was exposed to Kodak x-ray film between two intensifying screens at Ϫ80°C for autoradiography.
RESULTS

LacZ gene expression in prostate
The prostate tissues obtained from control and adenoviral vector-injected dogs were cryosectioned and stained with X-Gal to determine the in situ expression of lacZ. Endogenous X-Gal staining was undetectable ( Fig  1A) . AdRSVlacZ and all three prostate-specific Ad-lacZ had blue-staining cells (lacZ expression) after i.p. injection (Fig 1, B-D) . In general, AdRSVlacZ resulted in a higher percentage of blue-stained cells with greater blue color intensity than the prostate-specific Ad-lacZ vectors (Fig 1, compare B with C and D) . Protein extracts were also isolated from canine prostates and subjected to colorimetric ␤-gal assay to measure the lacZ enzymatic activity. The prostate tissues transduced by all of the Ad-lacZ vectors had ␤-gal activity: AdRSVlacZ had the highest activity (4.87 U of ␤-gal per mg protein) compared with AdPSAlacZ (2.86 U of ␤-gal per mg protein), AdPBlacZ (2.29 U of ␤-gal per mg protein), and AdMMTVlacZ (1.86 U of ␤-gal per mg protein) (Fig 2) . The relative differences in AdRSVlacZ versus AdPSAlacZ, AdPBlacZ, and AdMMTVlacZ were 1.7-, 2.1-, and 2.6-fold, respectively. These results showed that Ad-lacZ vectors were able to transduce and express the lacZ transgene in the canine prostate by i.p. injection.
Detection of adenovirus in various tissues
To determine whether adenovirus dissemination occurred following i.p. injection, DNA was extracted from various canine tissues harvested at necropsy and subjected to PCR analysis for adenoviral sequences. More specifically, the PCR primers flanked an 860-bp sequence of the adenoviral genome. Regardless of the promoter type, all adenoviral vector-injected prostates had an intense 860-bp signal band, confirming that the majority of adenovirus transduction occurred in the prostate itself (Fig 3) . To increase the sensitivity of adenoviral tissue detection, the 860-bp PCR product amplified from control adenoviral plasmid was isolated as a probe for the Southern hybridization of the PCR gel blot. Adenoviral sequences were indeed found in other tissues, which is consistent with the occurrence of adenoviral dissemination following i.p. injection. AdRSVlacZ disseminated to the vas deferens (perhaps as a result of reflux from the ejaculatory ducts of the injected prostate) and external iliac artery. AdPSAlacZ and AdMMTVlacZ were also detected in the vas deferens as well as in bladder tissues. An i.p. injection of AdPBlacZ resulted in adenoviral vector dissemination to the bladder, heart, and liver (Fig 4) . Thus, following an i.p. injection of adenoviral vectors, the majority of adenoviral vector DNA was found in the prostate. However, adenovirus may disseminate to other organs and tissues, primarily the bladder and vas deferens. The presence of adenoviral DNA in the heart, blood vessels, and liver tissues may be explained by the fact that these organs receive a high percentage of cardiac output (blood flow).
Detection of lacZ expression in tissues affected by adenoviral vector dissemination
To determine whether Ad-lacZ was expressed in tissues containing adenoviral DNA, RNA was extracted from various canine tissues and subjected to RT-PCR analysis. The primers used for RT-PCR were specific for E. coli lacZ and flanked a 1036-bp internal sequence of the lacZ gene. Consistent with X-Gal staining and ␤-gal assays, RT-PCR followed by gel electrophoresis showed that a 1036-bp band was present in the prostates following i.p. adenoviral injection (data not shown). The integrity of the RNA samples from various tissues was demonstrated by RT-PCR of the housekeeping gene ␤-actin (Fig 5) . Furthermore, a direct PCR of RNA samples using primers specific for ␤-actin did not shown any signal (data not shown), indicating that there was no DNA contamination in our RNA samples that had been purified by a Qiagen RNeasy kit. To increase the level of RT-PCR sensitivity, the 1036-bp PCR product from the control lacZ plasmid was isolated as a probe for Southern hybridization of the RT-PCR gel blot to evaluate lacZ RNA expression (Fig 6) . The control viral vector AdRSVlacZ had lacZ mRNA expression in all tissues in which adenoviral vectors had disseminated (compare Fig 6A with Fig 4A) . This finding was expected, because RSV has nonspecific promoter activity. Interestingly,some organs such as the liver, lung, spleen, bladder, and kidney that had no detectable adenoviral sequences in PCR Southern hybridization also had lacZ mRNA expression by RT-PCR Southern hybridization, implying that an RT-PCR of the lacZ transgene may be more sensitive than a PCR of adenoviral sequences (compare Fig 6A with Fig 4A) . In contrast, AdPSAlacZ and AdMMTVlacZ had no expression of lacZ in the vas deferens and bladder (compare Fig 4B with Fig 6B; compare Fig 4C with Fig 6C) . Similarly, AdPBlacZ lacked detectable lacZ mRNA transcripts in the bladder, heart, and liver (compare Fig 4D with Fig 6D) . These findings confirm that, although prostate-specific adenoviral vectors do disseminate following i.p. injection, the adenoviral lacZ transgene was only expressed in the prostate. 
DISCUSSION
Most viral-based vectors for gene therapy are tissuenonspecific, using endogenous viral promoters. However, gene expression may occur in unintended, nontargeted tissues that may potentially cause systemic toxic effects, especially if a suicide gene is the expressed gene. For example, if a prodrug enzyme is used under the control of a constitutive promoter for prostate cancer gene therapy, all of the cells in contact with the viruses, including nonprostatic tissues, would be transduced and killed by the prodrug treatment, resulting in potential dangerous systemic toxicity. One approach that may theoretically overcome this dilemma is to use cis-acting control sequences that restrict expression of the therapeutic cDNA to particular cell types. Numerous tissuespecific regulatory sequences have been identified and may potentially be used in this manner. 22, 23 Several cell type-specific gene expression systems have been developed using replication-deficient adenovirus and celltype-specific promoters. Expression of the transgene in recombinant adenovirus carrying neural cell type-specific promoters is highly restricted in neural cells, 24 and adenovirus carrying human factor VIII under the control of the liver-specific promoter limited the expression of factor VIII to the liver. 25 Several approaches using transcriptional control strategies have been reported in prostate cancer gene therapy. Retroviruses carrying antisense c-myc under the control of MMTV LTR effectively inhibited the growth of xenograft tumors of prostate cancer DU145 cells in nude mice; 12 adenoviruses carrying PSA-luciferase reporter gene were injected into xenograft prostate tumors, and various organs were harvested for luciferase analysis; 26 adenoviruses expressing therapeutic toxic gene under the control of an osteoblastic tissue-specific promoter specifically targeted prostate cancer metastasis in the bone; 27 and adenoviruses that are prostate-attenuated replication-competent by driving adenoviral replication of the E1a gene under the control of the PSA promoter effectively inhibited PSA-producing prostate cancer LNCaP cells in vitro and in vivo. 28 Other ongoing projects in this area include the use of the longer PSA or PB promoter (our unpublished data), addition of the enhancer, and modification of the adenoviral vectors to minimize the interference of the viral genome to retain the higher and prostate tissue-specific expression (Zhang WW, unpublished observations). However, all of these approaches have limited application due to the use of only one prostate-specific promoter. For example, PSA promoter can only activate transgene in PSAproducing, androgen-sensitive prostate cancer LNCaP 28 the latter type is most likely the malignant cell type seen in advanced prostate cancer patients whose prostate cancer growth becomes androgen-independent after the initial androgen deprivation treatment fails. Therefore, a study comparing several different prostate-specific promoters may be useful for choosing the right promoter for the different stage prostate cancer for the optimal therapeutic effect.
In this study, replication-deficient recombinant adenoviral vectors carrying the lacZ reporter gene driven by three different prostate-specific promoters were investigated to determine the degree of in vivo tissue specificity and level of activity following i.p. injection. To our knowledge, this is the first study to compare three different prostate-specific promoters along with the RSV promoter in vivo in a canine model. The unique advantage of using a canine model is that the dog prostate most closely mimics the human prostate in term of anatomy and pathology: dogs develop benign prostatic hyperplasia and prostate cancer when aging. Therefore, the study done in the canine prostate may reflect the more natural situations as to the human prostate environment compared with xenograft human prostate tumors or prostates from other animals. Interestingly, the three prostate-specific Ad-lacZ tested (PSA, PB, and MMTV LTR) expressed the lacZ gene only in the prostate and not in any of the other tissues in which adenoviral vectors had disseminated. In contrast, the control adenoviral vector AdRSVlacZ expressed lacZ both in the prostate and in the tissues that contained disseminated adenoviral sequences. The RSV promoter was stronger than the three prostate-specific promoters, suggesting that PSA, PB, and MMTV LTR promoters can be used to drive transgene expression specifically in the prostate, although with reduced promoter activity.
X-Gal staining and ␤-gal assays of the cultured prostate cancer PPC-1 cells transduced by these Ad-lacZ showed that AdRSVlacZ had a much higher level of lacZ expression than the prostate-specific Ad-lacZ vectors in vitro: prostate-specific Ad-lacZ required a 10-fold higher multiplicity of infection than AdRSVlacZ to obtain similar levels of lacZ expression. 29 However, the relative differences in promoter activity between control RSV promoters and prostate-specific promoters were smaller in vivo than in vitro. One explanation for this greater than predicted level of prostate-specific promoter activity is that prostate-specific promoters were exposed to more endogenous transactivators in the in vivo real prostate environment.
Tissues such as the vas deferens and bladder seems to be common sites for adenovirus dissemination following i.p. injection. This may more likely represent the direct extension of adenovirus rather than viral dissemination, as retrograde urethral and ejaculatory ductal reflux may account for this unusual pathway of adenoviral dissemination following i.p. injection. Alternatively, the presence of virus in the heart and liver may be due to other factors, such as a true viral dissemination with transduction of those organs that receive a high percentage of cardiac output. Nevertheless, none of the organs that contained disseminated prostate-specific Ad-lacZ vectors had lacZ expression. In contrast, all organs with AdRSVlacZ vectors had lacZ expression (Figs 4 and 6) . The results of this study consistently demonstrated that in vivo lacZ expression was essentially confined to the prostate tissue.
In conclusion, prostate-targeted adenoviral vectors containing either a PSA, PB, or MMTV LTR prostatespecific promoter were able to transduce and express lacZ specifically in the prostate in vivo by i.p. injection. Although adenoviral dissemination occurred, only prostate tissues expressed the lacZ transgene. Thus, the development of novel prostate-specific adenoviral vectors using tissue-specific promoters may be a useful strategy for prostate cancer gene therapy.
